NEXTCURE, INC Available-for-sale Securities, Gross Realized Losses
NEXTCURE, INC (NXTC) reported Available-for-sale Securities, Gross Realized Losses of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-03-12.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses · last filed 2020-03-12
- NEXTCURE, INC available-for-sale securities, gross realized losses for fiscal 2019 was $0.00.
| Period end | Available-for-sale Securities, Gross Realized Losses 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |